Gabapentin
Brand names: Gabapentin, Gralise, Gabapentin Er, Neurontin
Part of: Gabapentin & pregabalin
At a glance
- Medicare prescriptions, 2024
- 35,085,700
- Medicare drug cost
- $530.9M
- Average cost per prescription
- $15.13
- Clinicians who prescribed it
- 364,106
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Gabapentin Capsules, USP are indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 26.1%
- Internal Medicine 20.4%
- Nurse Practitioners 20.0%
- Physician Assistants 7.5%
- Pain Medicine 4.3%
- Neurology 4.2%
- General Practice 2.4%
- Psychiatry 1.9%
- Physical Medicine & Rehabilitation (PM&R) 1.7%
- Psychiatric Nurse Practitioners 1.4%
- Rheumatology 1.4%
- Geriatric Medicine 1.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 17% from 2019 to 2024.
Biggest change by state since 2019
- Delaware +34%
- Connecticut +32%
- Maryland +32%
- Hawaii +31%
- Alaska +28%
- Tennessee (smallest change) +0%
- West Virginia (smallest change) +2%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Almatica Pharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 300 mg | white oval tablet, 16 mm | SLV 300 |
| 450 mg | red oval tablet, 17 mm | ALM 450 |
| 600 mg | brown oval tablet, 19 mm | SLV 600 |
| 750 mg | yellow oval tablet, 19 mm | ALM 750 |
| 900 mg | pink oval tablet, 20 mm | ALM 900 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 16 mm | SG 179 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | brown capsule, 22 mm | AHD 400 |
Time Cap Laboratories, Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 16 mm | 103 |
| 300 mg | yellow capsule, 19 mm | 104 |
| 400 mg | orange capsule, 21 mm | 105 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
7 recalls since 2020
- Oct 2025 · The Harvard Drug Group LLC · Class II
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity. - Jun 2025 · The Harvard Drug Group LLC · Class II
Defective container; blister packaging inadequately sealed. - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Mar 2025 · Sun Pharmaceutical Industries Inc · Class III
Cross Contamination - Apr 2023 · The Harvard Drug Group · Class III
Product mixup: one foreign tablet found in product. - May 2020 · Invagen Pharmaceuticals, Inc. · Class III
Failed Impurities/Degradation Specifications; failure of Impurity A test at the 12-month long-term stability testing. - Mar 2020 · Aurobindo Pharma USA Inc. · Class II
CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.